Profile data is unavailable for this security.
About the company
Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
- Revenue in EUR (TTM)1.16bn
- Net income in EUR116.03m
- Incorporated2017
- Employees3.55k
- LocationDermapharm Holding SELil-Dagover-Ring 7GRUENWALD 82031GermanyDEU
- Phone+49 89641860
- Fax+49 8 964186130
- Websitehttps://ir.dermapharm.de/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhejiang Jiuzhou Pharmaceutical Co Ltd | 654.15m | 88.29m | 1.91bn | 5.00k | 21.63 | 1.78 | -- | 2.91 | 0.8113 | 0.8113 | 6.07 | 9.84 | 0.493 | 1.97 | 4.84 | 1,070,948.00 | 6.65 | 9.23 | 7.91 | 12.19 | 34.65 | 33.78 | 13.50 | 15.64 | 2.42 | -- | 0.0152 | 39.55 | -6.57 | 20.67 | -41.34 | 20.58 | 22.64 | 8.45 |
| Nippon Shinyaku Co Ltd | 912.69m | 164.07m | 1.93bn | 2.24k | 11.28 | 1.19 | 9.70 | 2.12 | 443.17 | 443.17 | 2,465.26 | 4,211.80 | 0.5421 | 1.17 | 3.19 | 74,028,980.00 | 9.75 | 10.89 | 10.81 | 12.74 | 67.29 | 63.93 | 17.98 | 17.67 | 4.04 | -- | 0.0089 | 30.58 | 8.08 | 6.56 | 25.94 | 14.06 | 80.48 | 7.59 |
| China Resources Jingzhng Phrmctcl Co Ltd | 537.01m | 102.27m | 1.94bn | 4.18k | 18.88 | 4.18 | -- | 3.61 | 1.32 | 1.32 | 6.94 | 5.98 | 0.6755 | 3.53 | 11.30 | 1,051,350.00 | 14.12 | 11.45 | 23.31 | 16.72 | 60.96 | 64.04 | 20.91 | 18.23 | 1.33 | -- | 0.0348 | 93.25 | -2.59 | 12.61 | 9.67 | 11.20 | 30.67 | 36.85 |
| Nanjing King-Frind Bchmcl Phrmctcl C Ltd | 459.40m | 79.37m | 1.94bn | 1.36k | 24.10 | 2.35 | -- | 4.22 | 0.4079 | 0.4079 | 2.35 | 4.18 | 0.3812 | 0.6322 | 3.82 | 2,765,677.00 | 6.59 | 8.38 | 8.99 | 12.03 | 41.12 | 44.95 | 17.28 | 19.72 | 1.35 | -- | 0.2644 | 23.22 | -0.1984 | 9.70 | 536.09 | 6.43 | 34.44 | -6.04 |
| Guobang Pharma Ltd | 725.82m | 106.62m | 1.95bn | 4.00k | 18.19 | 1.93 | -- | 2.69 | 1.57 | 1.57 | 10.68 | 14.80 | 0.5603 | 3.06 | 7.04 | 1,484,531.00 | 8.20 | 9.52 | 10.33 | 12.47 | 24.67 | 27.10 | 14.64 | 14.91 | 2.30 | -- | 0.1038 | 24.76 | 10.12 | 9.15 | 27.61 | 19.94 | -7.08 | -- |
| Dermapharm Holding SE | 1.16bn | 116.03m | 1.98bn | 3.55k | 17.11 | 3.05 | 10.46 | 1.71 | 2.15 | 2.15 | 21.54 | 12.06 | 0.5472 | 1.13 | 9.18 | 321,361.20 | 5.39 | 7.72 | 6.40 | 9.04 | 66.57 | 63.64 | 9.85 | 11.81 | 1.04 | 4.88 | 0.61 | 52.26 | 4.00 | 11.00 | 82.44 | 8.07 | -3.81 | -- |
| Bavarian Nordic A/S | 921.90m | 327.29m | 2.01bn | 1.74k | 6.21 | 1.13 | 4.77 | 2.18 | 30.57 | 30.57 | 85.79 | 168.13 | 0.4732 | 1.34 | 6.08 | 4,274,910.00 | 16.80 | 3.31 | 20.18 | 4.02 | 54.33 | 52.68 | 35.50 | 9.80 | 2.43 | -- | 0.0101 | 0.00 | -19.06 | 53.88 | -33.03 | -- | -8.77 | -- |
| Piramal Pharma Ltd | 824.61m | -15.21m | 2.02bn | 7.13k | -- | -- | 31.37 | 2.45 | -1.26 | -1.26 | 66.90 | -- | -- | -- | -- | 12,449,300.00 | -- | -- | -- | -- | 64.63 | -- | -1.84 | -- | -- | 0.5519 | -- | -- | 11.99 | -- | 411.39 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Mawer Investment Management Ltd.as of 25 Jun 2025 | 1.60m | 2.97% |
| Grandeur Peak Global Advisors LLCas of 31 Oct 2025 | 709.72k | 1.32% |
| DNCA Finance SAas of 30 Jun 2025 | 561.96k | 1.04% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 554.83k | 1.03% |
| Janus Henderson Investors UK Ltd.as of 31 Dec 2025 | 360.81k | 0.67% |
| Amundi Asset Management SASU (Investment Management)as of 02 Feb 2026 | 357.76k | 0.66% |
| Danske Bank A/S (Investment Management)as of 31 Jan 2026 | 339.88k | 0.63% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 288.16k | 0.54% |
| DWS Investment GmbHas of 30 Dec 2025 | 247.67k | 0.46% |
| abrdn Investment Management Ltd.as of 31 Oct 2025 | 235.13k | 0.44% |
